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Objective: Toll-like receptor 4 (TLR4) is one of the key players in the development of 
many autoimmune diseases. To determine the possible role of TLR4 in polymyositis (PM) 
development, we collected muscle samples from PM patients and mice subjected to an 
experimental autoimmune myositis (EAM) model.
Methods: We measured TLR4–MyD88 pathway-related factors, interferon-γ (IFN-γ), and 
interleukin-17A (IL-17A) in EAM mice and PM patients. Then, we observed the changes 
of above factors and the inflammatory development of EAM mice with TLR4 antagonist 
TAK-242, IFN-γ, or IL-17A antibody treatment.
results: The expression of TLR4, MyD88, and NF-κB was significantly upregulated in 
the muscle tissues both in 22 patients with PM and in the EAM model. As expected, 
increased levels of various cytokines, such as IL-1β, IL-6, IL-10, IL-12, tumor necrosis 
factor-α, TGF-β, IFN-γ, and IL-17A, were evident in the serum of EAM mice. Moreover, 
mRNA expression levels of IFN-γ and IL-17A were significantly increased in both PM 
patients and EAM mice. Consistently, the levels of these factors were positively cor-
related with the degree of muscle inflammation in EAM mice. However, when EAM mice 
were treated with TLR4 antagonist TAK-242, the expression of IFN-γ and IL-17A was 
decreased. When the cytokines were neutralized by anti-IFN-γ or anti-IL-17A antibody, 
the inflammatory development of EAM exacerbated or mitigated.
Abbreviations: PM, polymyositis; EAM, experimental autoimmune myositis; TLR4, toll-like receptor 4; MyD88, myeloid 
differentiation primary response gene 88; NF-κB, nuclear factor-κB; IFN-γ, interferon-γ; IL-17A, interleukin-17A.
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conclusion: The present study provided the important evidence that the TLR4–MyD88 
pathway may be involved in the immune mechanisms of PM by mediating IFN-γ and 
IL-17A.
Keywords: polymyositis, toll-like receptor 4–MyD88 pathway, interferon-γ, interleukin-17a, eaM model
inTrODUcTiOn
Polymyositis (PM) is a major clinical subtype of the idiopathic 
inflammatory myopathies, which is classified as an autoimmune 
disease (1–4) and still lacks effective therapy. Females are affected 
more often than males at a ratio of approximately 2:1. The average 
age of onset of adult PM is between 52 and 56 years of age (5). The 
clinical symptoms are characterized by acute or subacute progres-
sive muscle weakness, endomysia inflammatory cell infiltration, 
creatine kinase elevation, and abnormal electromyogram (EMG) 
(6). PM is histologically characterized by the presence of endomy-
sial inflammatory infiltrates consisting of CD8+ T cells invading 
non-necrotic muscle fibers that express major histocompatibility 
complex class I (MHC-I) molecules on the sarcolemma (7). Thus, 
CD8/MHC-I complex has become a characteristic diagnostic tool 
for PM. However, the mechanisms underlying PM pathological 
process are still largely unknown.
Toll-like receptor 4 (TLR4) is an important member of the 
TLR family, which was discovered in Drosophila as a leucine-rich 
repeat structure that initiated the innate immune reaction and 
promoted the adaptive immune response (8). TLR4 is commonly 
expressed on mononuclear macrophages, dendritic cells, or 
B  cells and recognizes pathogen-associated molecular patterns 
on microbes (9–11). TLR4 transmits signals via at least five 
cytosolic adaptor molecules including myeloid differentiation 
primary response gene 88 (MyD88), TIR domain-containing 
adaptor protein, interleukin-1 (IL-1) receptor-associated kinase, 
tumor necrosis factor (TNF) receptor-associated factor 6, and 
the early-phase of nuclear factor-κB (NF-κB), which leads to the 
induction of proinflammatory cytokines (8, 12). Once activated, 
the TLR4–MyD88 pathway may lead to induction of dendritic 
cells and inflammatory cytokines such as interferon-γ (IFN-γ) 
and interleukin-17A (IL-17A) (13, 14). IFN-γ is a potent activator 
of macrophages, which is secreted by activated T cells, NK cells, 
or macrophages. IL-17 family cytokines are strong inducers of 
inflammatory diseases, which are secreted mainly by T helper 
cells (15, 16).
Previous studies have shown that TLR4 may play a critical 
role in various autoimmune diseases (17–22). For example, 
the expression of TLR4 was increased in rheumatoid arthritis, 
systemic lupus erythematosus, and multiple sclerosis. At pre-
sent, only a few reports show an increased expression of TLR4 
in a small group of PM patients (23). Our previous study also 
showed increased expression levels of TLR4, MyD88, and NF-κB 
mRNA in lymph nodes of a PM animal model (24). However, 
the detailed changes in molecules involved in the TLR4–MyD88 
signaling pathway, sequential inflammatory factors, and IFN-γ/
IL-17A-producing cells during the development of PM are not 
fully clarified. Therefore, in the present study, we examined the 
expression of molecules in the TLR4 pathway and the changes of 
the expression of IFN-γ and IL-17A in 22 PM patients and a PM 
animal model, treated the mice with TLR4 antagonist TAK-242, 
and attempted to provide a full view of the effects of the TLR4 
signal by regulating IFN-γ and IL-17A on the development of 
PM pathology.
PaTienTs anD MeThODs
subjects
Patients and Laboratory Assessments
Muscle biopsies from patients with PM (n  =  22), diagnosed 
using the classification criteria of the European Neuromuscle 
Centre (ENMC), were used in our study. The samples were col-
lected from 2009 to 2012 in Xijing Hospital, the Fourth Military 
Medical University, Xi’an, China. The patients included 10 men 
and 12 women, whose mean age was 37 years (37 ± 15 years). The 
duration from symptom appearance to diagnosis ranged from 0.5 
to 12 months. Patient data was listed in Tables 1 and 2. Muscle 
biopsies from six patients with periodic paralysis, showing nor-
mal histological findings, were used as the controls. Serum levels 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 
lactate dehydrogenase (LDH), alanine transaminase (ALT) and 
aspartate transaminase (AST), antinuclear antibody (ANA), 
the Jo-1 antibody, RO-52 antibody, anti-Sjögren’s syndrome A 
antibody (SSA), anti-Sjögren’s syndrome B antibody (SSB), anti-
mitochondria antibody (AMA)-M2, anti-cardiolipin antibody 
(ACA), anti S-M2 antibody, and anti-Scl-70 antibody (Scl-70) 
were detected at the Department of Clinical Biochemistry 
Laboratory, Xijing Hospital. The EMGs were performed in 
the Neural Electrophysiological Laboratory of Department of 
Neurology, Xijing Hospital.
Animal Model
Female BALB/c mice at the age of 5–6  weeks (14–17  g) and a 
cony pig (300 g) were purchased from the Animal Center of the 
Fourth Military Medical University, Xi’an, China. The mice and 
cony pig were kept in specific pathogen-free conditions in an 
environmentally controlled room (23 ± 2°C, 55 ± 10% humid-
ity) on a 12 h-light/dark cycle, fed by sterilized fodder and water 
ad libitum. During feeding and study, the body weight and health 
status of mice were monitored in specific pathogen-free condi-
tions every day.
experimental autoimmune Myositis (eaM) 
Model
Myosin was purified from the skeletal muscle of the cony pig 
according to Perry’s method (25) with some modifications. The 
EAM model was performed based on a previous report (26) 
with several modifications. In brief, the mice were immunized 
twice with a 1-week interval. Myosin (1.5  mg) and inactive 
Mycobacterium tuberculosis (5  mg/ml, BD DIFCO, 231141) in 
Table 1 | clinical laboratory characteristics of patients with PM.
Patient sex age symptom 
duration 
(months)
cK (iU/l) lactate 
dehydrogenase 
(lDh) (iU/l)
aspartate 
transaminase 
(asT) (iU/l)
alanine 
transaminase 
(alT) (iU/l)
erythrocyte 
sedimentation 
rate (esr) 
(mm/h)
c-reactive 
protein 
(crP) 
(mg/l)
Using 
corticosteroid 
(Yes/no)
1 M 57 0.5 3,882 530 182 84 8 10.2 Y
2 F 32 12 2,252 669 132 103 26 0.97 N
3 F 32 12 6,311 968 411 173 30 5.28 Y
4 F 53 3 6,832 1,887 255 214 41 18.6 N
5 M 27 1 78 182 18 34 16 1.36 N
6 F 46 9 288 273 40 18 9 7.59 Y
7 M 56 8 7,421 1,260 303 223 7 11.62 Y
8 M 22 4 6,627 1,324 199 105 6 1.74 N
9 F 19 36 864 406 166 131 22 7.67 Y
10 F 25 7 3,146 960 132 98 2 2.43 Y
11 M 51 1.5 3,258 808 204 194 5 8.74 N
12 F 30 12 1,088 407 36 32 11 4.58 N
13 F 19 5 8,971 1,181 323 251 14 13.12 N
14 M 36 1 10,734 1,583 524 278 47 20.69 N
15 F 35 0.5 10,250 1,820 662 328 29 3.52 N
16 M 31 3 5,027 1,265 25 299 4 1.15 Y
17 M 36 9 1,151 295 69 65 17 21.17 N
18 F 6 1 5,107 1,467 320 266 33 6.14 N
19 F 37 5 2,288 756 182 60 36 1.42 N
20 M 40 48 15 169 29 159 12 84.14 Y
21 F 63 12 2,851 1,015 133 86 37 12.86 N
22 M 51 15 1,096 534 203 111 12 0.66 N
N = 22 F/M (12/10) 37 ± 15 9.3 ± 11.6 4,070.0 ± 3,322.1 898.1 ± 525.6 206.7 ± 166.7 150.5 ± 93.4 19.3 ± 13.4 11.2 ± 17.5 Y/N (8/14)
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complete Freund’s adjuvant (CFA, Sigma, F5881) were injected 
into the muscle tissue of one limb (the first immunization) and 
the tail base (the second immunization). Pertussis toxin (Sigma, 
P2980) was injected intraperitoneally (500 ng in 200 µl normal 
saline) during each immunization. All experimental procedures 
were reviewed and approved by the Animal Studies Committee 
of the Fourth Military Medical University, Xi’an, China and the 
animal study was carried out with the established institutional 
guidelines regarding animal use and care.
One hundred and eighty BALB/c mice were randomly divided 
into five groups: the controls were normal mice. EAM mice in the 
other four groups were euthanized with excessive anesthesia at 
the end of 1–4 weeks after animals were given myosin for induc-
ing EAM (n = 6, each group).
evaluation of Muscle strength
Muscle strength was evaluated using an inverted screen test as 
described in the literature (27). The method was performed using 
a 50 cm2 screen with 1 cm2 mesh. Mice were placed in the center 
of the screen and the screen was rotated to the inverted horizontal 
position. The time at which the mouse fell off was noted. The 
evaluation of muscle strength was measured by one investigator 
blinded to the immunization protocol used.
sample Preparation
For PM patients, muscle biopsy samples were removed from one 
side of the musculus biceps brachii or quadriceps femoris accord-
ing to a “semi-open” muscle biopsy technique. For the EAM 
model, muscle tissues were collected of the bilateral musculus 
biceps brachii and quadriceps femoris of each mouse. All the 
muscle samples were frozen immediately in isopentane with a 
container surrounded by liquid nitrogen and stored at −70°C 
until analysis. Blood samples of each mouse were collected in a 
1.5 ml tube, centrifuged for 25 min at 4°C, and stored at −70°C 
for a multiplex Luminex assay.
histological grading of inflammatory 
lesions and immunohistochemistry
Muscle tissues of PM patients and EAM mice were serially cut 
to 10 µm thick slides. For H&E staining, the slides were stained 
with hematoxylin and eosin to reveal the histology of the muscle. 
EAM sections were analyzed according to the criterion described 
in a literature (25). Four parts of muscle tissue of one section 
were each scored individually, the mean score of which represents 
the inflammatory level of one mouse. All fields of each section 
were analyzed. The histological severity of inflammation in each 
muscle block was graded as follows (26, 28): grade 1, a lesion 
involving a single muscle fiber or less than 5 muscle fibers; grade 2, 
a lesion involving 5–30 muscle fibers; grade 3, a lesion involv-
ing a muscle fasciculus; and grade 4, diffuse, extensive lesions. 
When multiple lesions with the same grade were found in a single 
muscle block, 0.5 points were added to the grade. All slides were 
evaluated independently by two investigators who were blinded 
to the immunization protocol that had been used. The differences 
in evaluation between the two observers were resolved via confer-
ence microscopy.
For IHC, the slides were fixed in 4% paraformaldehyde for 
20 min, and antigen-repaired in sodium citrate surrounded by 
Table 2 | clinical laboratory characteristics of patients with PM.
Patient antinuclear 
antibody 
(ana) (+/−)
Jo-1 (+/−) rO-52 
(+/−)
sjögren’s 
syndrome  
a antibody 
(ssa) (+/−)
sjögren’s 
syndrome  
b antibody 
(ssb) (+/−)
anti-mitochondria 
antibody 
(aMa)-M2 (+/−)
anti-cardiolipin 
antibody (aca) 
(+/−)
s-M2 
(+/−)
scl-70 (+/−)
1 − − − − − − − − −
2 − − − − − − − − −
3 + − + + − − − − −
4 + − + − − − − − −
5 − − − − − − − − −
6 − − + + − + + − −
7 + − + − − − − − −
8 + − − − − − − − +
9 + − + + − − − − −
10 + − − + − − − − −
11 + − − − − − − − −
12 + − − − − − − − −
13 + + + + − − − − −
14 + − − − − − − − −
15 + − − − − − − − −
16 + − − − − − − − −
17 − + − − − − − + +
18 + − − − − − − − −
19 + − − − − − − − −
20 − − − − − − − − −
21 + − + + + − − − −
22 + − − − − − − − −
N = 22 +/− (16/6) +/− (2/19) +/− (7/15) +/− (6/16) +/− (1/21) +/− (1/21) +/− (1/21) +/− (1/21) +/− (2/20)
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100°C water for 15 min. After endogenous peroxidase activity in 
tissues was blocked in 3% H2O2 for 30 min, the slides were incu-
bated with the primary antibody: rabbit anti-mouse TLR4 (1:50, 
Abcam, ab13556), rabbit anti-human TLR4 (1:50, Santa Cruz, 
sc-10741), rabbit anti-mouse/human IFN-γ (1:100, proteintech, 
15365-1-AP), and IL-17A (1:100, abcam, ab79056) overnight at 
4°C. After washing in PBS three times, the slides were incubated 
with biotin-labeled goat anti-rabbit IgG (Vector Labs, BA-1000) 
for 2  h at room temperature, followed by streptavidin-biotin 
horseradish peroxidase (Vector Labs, SA-5004) for 2 h. The tissues 
were covered with 3,3′-diaminobenzidine tetrahydrochloride 
(Sigma, D5637) reagent solution for the final color product. The 
sections were observed with a Leica DRM microscope and Nikon 
imaging system.
real-time rT-Pcr
mRNA transcripts of TLR4, MyD88, NF-κB, IFN-γ, and 
IL-17A were measured by RT-PCR. Total RNA from different 
samples was isolated in TRIZOL Reagent (Invitrogen Life 
Technologies, 15596-026) and reverse transcribed to cDNA 
with a PrimeScript® RT Master Mix kit (TaKaRa, DRR036A) 
according to the manufacturer’s instructions. The quantitative 
RT-PCR was performed on a Bio-Rad iQ5TM Optical System 
Software Version 2.0 (Bio-Rad Laboratory) with an SYBR® 
Premix Ex Taq™ II Kit (TaKaRa, DRR081A). The different 
primer sequences were listed in Table S1 in Supplementary 
Material. The PCR cycling parameters were 40 cycles of pre-
denaturation at 95°C for 30  s, denaturation at 95°C for 10  s, 
and annealing at 60°C for 20  s. Data analysis was performed 
using the delta–delta Ct method. The results were normalized 
to GAPDH expression.
cytokine Detection
The levels of IFN-γ, IL-1β, IL-6, IL-10, IL-12, IL-17A, TNF-α, and 
TGF-β in mouse serum were detected using a multiplex Luminex 
assay according to the manufacturer’s instructions (Milliplex MAP 
Mouse Cytokine/Chemokine Panel-Immunology Multiplex Assay, 
Milliplex MAP TGFβ1-Single Plex, Millipore Corporation, Billerica, 
MA, USA). The plates were analyzed on the Luminex 200™ system 
(MAP™ Technology, Austin, TX, USA).
eaM Mice injected with lPs, TaK-242, 
anti-iFn-γ, and anti-il-17a antibodies
Experimental autoimmune myositis mice were treated by intra-
venous injections daily after the first immunization with the 
TLR4 agonist lipopolysaccharide (LPS) (2 mg/kg, sigma, L2880) 
or theTLR4 antagonist TAK-242 (3  mg/kg, CALBIOCHEM, 
614316) for 14 days. EAM mice were treated by intraperitoneal 
injections of anti-IFN-γ (1.0  mg/mouse, weekly, Biolegend, 
506963) and anti-IL-17A (100 μg/mouse, every 3 days, Biolegend, 
505827) antibodies after the first immunization for 14 days. The 
mice were sacrificed 7 days after the last immunization. MyD88, 
NF-κB, IFN-γ, and IL-17A mRNA in muscle tissue were meas-
ured by RT-PCR. IFN-γ and IL-17A levels in serum were detected 
by Luminex.
statistics
All the data were shown as the mean ± SD, and differences between 
two groups were analyzed by one-way classification ANOVA 
and multiple groups by LSD using SPSS19.0 software. Normal 
distribution variance data between two groups were analyzed 
using a Pearson linear correlation, and a non-normal distribution 
FigUre 1 | immunohistochemistry of toll-like receptor 4 (Tlr4) in polymyositis (PM) patients and experimental autoimmune myositis (eaM) mice. 
(a–c) In muscle tissues of patients with PM, compared with the controls [Ctrl (A)], TLR4 was strongly expressed by infiltrating cells surrounding the muscle bundle, 
on the endomysial, and in the muscle fibers [indicated by arrows in (b,c)]. (D–i) In muscle tissues of mice with EAM, TLR4 expression was weak in the controls (D), 
began to be upregulated at 1 week after the first immunization (e), reached to the peak at 2 weeks (F), and attenuated at 3 weeks (g) and 4 weeks (h).  
The nuclei were counterstained with hematoxylin. **P < 0.001 vs. the controls (Ctrl). Scale bars: 50 µm.
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variance using Spearman rank correlation. Significance was con-
sidered at P < 0.05.
resUlTs
clinical and laboratory Features  
of PM Patients
Our data from PM patients showed elevated levels of serum ESR, 
CRP, LDH, ALT, and AST, some of which were over 10 times the 
normal ceiling value (Table 1). Although PM is often diagnosed 
by clinical symptoms, kinase examination, and muscle biopsy, 
more and more studies indicated that autoantibodies also existed 
in the PM patients (5, 29, 30). Consistently, of the 22 PM patients 
in our study, 16 patients expressed ANA, 2 expressed the Jo-1 
antibody, 7 expressed RO-52 antibody, 6 expressed SSA antibody, 
1 expressed SSB antibody, 1 expressed AMA-M2, 1 expressed 
ACA, 1 expressed anti S-M2 antibody, and 2 expressed Scl-70 
antibody (Table 2).
The EMGs of all PM patients revealed abnormal findings: 
increased insertional and spontaneous activity in the form of 
fibrillation potentials, positive sharp waves, complex repetitive 
discharges, short duration, small amplitude, or polyphasic motor 
unit action potentials (data not shown).
changes in expression of Tlr4, MyD88,  
or nF-κb in PM Muscle Tissues
IHC showed that TLR4+ cells were present in the muscle fibers, 
endomysial, and around muscle bundles in the muscle tissues of 
PM patients, whereas no obvious TLR4+ cells were observed in 
the controls (Figures 1A–C). TLR4 expression was elevated in 
EAM mice compared to the controls, and the maximal level was 
observed after the first immunization (Figures 1D–I).
Real-time PCR assays were performed to confirm the results 
of the IHC. Our results showed that the relative mRNA levels of 
TLR4 (26.28 ± 6.41, P < 0.001) and its downstream factors MyD88 
(23.43 ± 3.33, P < 0.001) and NF-κB (4.67 ± 1.24, P < 0.001) were 
significantly upregulated in PM patients compared to those of 
their respective controls (4.97 ± 2.59, 4.99 ± 2.50, and 0.94 ± 0.23) 
(Figure 2A). Similar results were also observed in EAM mice. At 
2 weeks after the first immunization, the relative mRNA levels of 
TLR4 (16.77 ± 0.93, P < 0.001), MyD88 (63.71 ± 5.30, P < 0.001), 
and NF-κB (6.45 ± 0.86, P < 0.001) were significantly elevated 
compared with their respective controls (0.54 ± 0.26, 2.00 ± 0.58, 
FigUre 2 | The changes in mrna expression of toll-like receptor 4 (Tlr4) pathway-related molecules in polymyositis (PM) patients and 
experimental autoimmune myositis (eaM) mice. (a) mRNA expression of TLR4, MyD88, and NF-κB were significantly increased in muscle tissues of biopsy 
samples from PM patients compared with the controls. (b) Compared with the controls, mRNA expression of TLR4, MyD88, and NF-κB were elevated in muscle 
tissues of EAM mice at 2 weeks after the first immunization. (c) Compared with the controls, mRNA expression of TLR4, MyD88, and NF-κB were decreased  
in the spleen of EAM mice at 2 weeks. **P < 0.001 vs. the controls (Ctrl).
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and 1.53 ± 0.29) (Figure 2B). It was noted that at 3 or 4 weeks 
after the first immunization, the expression of TLR4, MyD88, and 
NF-κB was recovered but still higher than that of the controls. 
Interestingly, in contrast to muscle tissue, TLR4 transcripts 
(0.71 ± 0.04, P < 0.001), MyD88 (0.48 ± 0.04, P < 0.001), and 
NF-κB (0.51 ± 0.09, P < 0.001) were significantly decreased in 
the spleen of EAM mice compared with controls (1.12 ±  0.11, 
1.52 ±  0.28, 1.23 ±  0.15) (Figure  2C). Therefore, these results 
showed increased levels of TLR4, MyD88, and NF-κB in the 
muscle tissues of PM patients and EAM mice.
changes in expression levels of 
cytokines in eaM Mice
Liquid chip assays were used to examine the levels of various 
cytokines in the serum of EAM mice at 1 ~ 4 weeks after the first 
immunization. At 1 week, the levels of IL-6 (76.13 ± 11.91 pg/ml), 
and IL-10 (14.87 ± 3.47 pg/ml) were prominently elevated com-
pared with controls (19.68 ± 5.63, 4.34 ± 0.30 pg/ml, P < 0.001). 
At 2 weeks, IFN-γ (43.05 ± 5.97 pg/ml), IL-1β (27.7 ± 5.25 pg/ml), 
IL-12 (13.39 ± 3.11 pg/ml), IL-17 A (49.35 ± 19.87 pg/ml), TNF-α 
(47.87 ± 6.70 pg/ml), and TGF-β (110.00 ± 12.17 ng/ml) reached 
their maximal levels compared with the controls (1.66 ±  0.98, 
1.98 ± 0.90, 1.52 ± 0.24, 3.86 ± 0.70, 1.68 ± 1.03, 50.50 ± 13.55, 
P < 0.001). At 3 weeks, the cytokine levels decreased but were still 
higher than those of the controls. Most of the cytokines except 
TNF-α almost recovered to control levels at 4 weeks (Figure 3). 
Overall, the levels of cytokines were elevated 1–3 weeks after the 
first immunization.
involvement of iFn-γ and il-17a in PM 
Patients and eaM Mice
Various inflammatory cytokines could promote the differentia-
tion from naïve T cells into functional T cells, which as well as 
macrophages are involved in various autoimmune diseases by 
secreting IFN-γ and IL-17A and so on (16). The mRNA levels of 
IFN-γ (39.02 ± 6.86) and IL-17A (26.43 ± 5.49) were elevated, 
respectively, in the muscle tissue of PM patients compared with 
the controls (0.87 ± 0.35, 6.74 ± 3.87, respectively, P < 0.001) 
(Figures  4C,F). Similar results were also found in the EAM 
mice. At 2  weeks after the first immunization, the relative 
mRNA levels of IFN-γ (49.98 ± 8.83) and IL-17A (32.15 ± 3.44) 
were markedly increased compared with their respective 
FigUre 3 | The changes in levels of inflammatory cytokines in the serum of experimental autoimmune myositis (eaM) mice at 1–4 weeks after the 
first immunization. The concentrations of IFN-γ (a), IL-1β (b), IL-6 (c), IL-10 (D), IL-12 (e), IL-17A (F), TGF-β (g), and tumor necrosis factor (TNF)-α (h) were 
detected by a Luminex assay. **P < 0.001, *P < 0.01, #P < 0.05, nsP > 0.05, vs. the controls (Ctrl).
FigUre 4 | The changes of interferon-γ (iFn-γ) and interleukin-17a (il-17a) in polymyositis (PM) patients and experimental autoimmune myositis 
(eaM) mice. (a–F) As compared with the controls (Ctrl), the expression of IFN-γ and IL-17A in the biopsy samples from PM patients were increased. (g–l) 
Compared with the controls, the expression of IFN-γ and IL-17A in the muscle of EAM mice were significantly increased. **P < 0.001, *P < 0.01, #P < 0.05, vs.  
the controls (Ctrl). The nuclei were counterstained with hematoxylin. Scale bars: 50 µm.
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controls (2.54 ± 1.50 and 1.25 ± 0.21, respectively, P < 0.001) 
(Figures  4I,L). At 3 or 4  weeks after the first immunization, 
their expression was attenuated but still higher than that of 
the controls. Moreover, IHC showed that IFN-γ+ and IL-17A+ 
cells are increased in the PM patients (Figures 4B,E) and EAM 
mice at 2  weeks(Figures  4H,K) compared with the controls 
(Figures 4A,D,G,J). Unexpectedly, the expression of these fac-
tors in the spleen was decreased compared with their respective 
controls (Figure S1 in Supplementary Material). Therefore, our 
results revealed that IFN-γ and IL-17A producing cells may be 
involved in the development of PM.
correlations between PM severity and 
Tlr4-related Factors, iFn-γ, or il-17a
To determine the severity of EAM in the mice, inflammatory 
lesion grading was evaluated according to a previous report 
(see the Methods section). HE staining results showed that at 
2  weeks after the first immunization, more inflammatory cells 
and damaged muscle fibers were evident than at 1, 3, or 4 weeks 
(Figure  5A). Histological grading of inflammatory lesions was 
shown in Figure 5B. Consistent with these results, at 2 weeks, 
mouse muscle strength indicated by the duration a mouse staying 
in the inverted screen (63.13 ±  6.42  s) was worse than that of 
the controls (2,241.8 ±  162.63  s, P <  0.001) and other groups 
(1 week, 527.15 ± 33.86 s, P < 0.001; 3 weeks, 152.98 ± 3.45 s, 
P =  0.047; 4  weeks, 171.97 ±  3.36  s, P =  0.018) (Figure  5C). 
We performed a Pearson linear correlation to analyze the cor-
relations of PM severity with TLR4-related factors, including 
TLR4, MyD88, NF-κB, IFN-γ, or IL-17A expression, respectively. 
Our results showed that the mRNA expression levels of TLR4, 
MyD88, NF-κB, IFN-γ, or IL-17A in muscle tissue of EAM mice 
were positively correlated with grading inflammatory lesions 
(r = 0.963, r = 0.952, r = 0.917, r = 0.923, r = 0.962, respectively, 
P < 0.001) (Figure 5D).
requirement of Tlr4–MyD88 signaling  
in the Development of PM
Part of TLR4 signaling is dependent on MyD88 (8). In muscle 
tissue of EAM mice, the TLR4 agonist LPS exacerbated the 
development of PM (Figures  6A–C), and upregulated the 
expression of MyD88 (84.60  ±  2.61), NF-κB (13.01  ±  1.51), 
IFN-γ (73.30 ± 3.46), and IL-17A (51.28 ± 6.48), compared with 
the EAM group treated with normal saline only (63.71 ± 5.30, 
6.45 ± 0.86, 49.98 ± 8.83, 32.15 ± 3.44, respectively, P < 0.001) 
(Figures 6G–J). However, the TLR4 antagonist TAK-242 mitigated 
the inflammatory development of PM (Figures  6A,B,D), and 
downregulated the expression of MyD88 (44.02 ± 3.70), NF-κB 
(3.51 ± 0.37), IFN-γ (30.87 ± 2.38), and IL-17A (22.60 ± 2.01), 
compared with the EAM group treated with normal saline only 
(63.71 ± 5.30, 6.45 ± 0.86, 49.98 ± 8.83, 32.15 ± 3.44, respectively, 
P < 0.001) (Figures 6G–J). Consistently, the levels of IFN-γ and 
IL-17A were increased or decreased in the serum of EAM mice 
treated with LPS (281.14 ±  38.78, P <  0.001; 99.94 ±  11.06, 
P < 0.001) or TAK-242 (41.99 ± 6.47, P = 0.007; 49.20 ± 4.52, 
P < 0.001), respectively, compared with the normal saline group 
(76.78 ± 7.14, 74.07 ± 5.91) (Figures 6K,L). Together, these data 
indicated that TLR4 signaling was involved in the PM and played 
a pivotal role in EAM.
involvement of Tlr4-Mediated iFn-γ and 
il-17a in the Development of eaM
The expression of TLR4-mediated IFN-γ and IL-17A was 
elevated in muscle tissue of PM patients and EAM mice as well 
as in the EAM serum, implying their important roles in the PM. 
To confirm this point, EAM mice were injected intraperito-
neally with anti-IFN-γ antibody or anti-IL-17A antibody. The 
grading of inflammation increased in EAM mice treated with 
IFN-γ antibody (4.23 ± 0.30) (Figures 7C,E) but decreased with 
IL-17A antibody (2.63 ± 0.11) (Figures 7D,E) significantly com-
pared with EAM mice (3.38 ± 0.14, P < 0.001) (Figures 7B,E). 
However, the EAM mice treated with anti-IFN-γ antibody 
had weaker muscular strength (60.85 ± 6.27) but had stronger 
muscular strength (595.00 ± 85.73) with anti-IL-17A antibody 
treatment compared with EAM mice (121.07 ± 18.52, P < 0.001) 
(Figure 7F). The expression of IFN-γ mRNA (3.75 ± 0.41) in the 
muscle tissue and IFN-γ (24.13 ± 2.93 pg/ml) in the serum were 
downregulated with IL-17A antibody compared with EAM mice 
(8.63 ± 0.90, 47.89 ± 7.32, respectively, P < 0.001) (Figures 7G,I) 
but IL-17A mRNA(24.47 ±  2.72) and IL-17A(118.33 ±  13.01 
pg/ml) treated with anti-IFN-γ antibody were upregulated 
compared with EAM mice (8.82 ±  1.28, 59.08 ±  9.18, respec-
tively, P  <  0.001) (Figures  7H,J). These data suggested that 
TLR4-mediated IFN-γ and IL-17A may be responsible for the 
inflammatory development of EAM.
DiscUssiOn
A group of studies have demonstrated that TLR4 plays an 
important role in autoimmune diseases (15). In this work, we 
showed a possible involvement of TLR4 and its downstream 
effectors, MyD88 and NF-κB, in the development of PM in 
human patients and in an EAM mouse model. Furthermore, we 
found that IFN-γ- and IL-17A-producing cells were involved 
and dependent on the TLR4–MyD88 pathway in the pathologi-
cal progression of PM.
Toll-like receptor 4 was proposed to play an important role 
in various autoimmune diseases, such as rheumatoid arthritis, 
systemic lupus erythematosus, and multiple sclerosis (19–21). 
Our previous study also showed increased expression levels of 
TLR4 and its downstream effectors in the lymph nodes in a PM 
animal model (24). As an extended study on PM pathology, 
here, we analyzed the changes in TLR4 expression using muscle 
biopsies from 22 PM patients and EAM mice. In PM patients, 
TLR4 expression was significantly increased compared with that 
of patients with periodic paralysis. Our results were consistent 
with the previous reports (23, 31). In EAM mice, we revealed 
a dynamic change of TLR4 expression, which reached a peak 
2 weeks after the first immunization. Furthermore, we analyzed 
changes in the expression of MyD88 and NF-κB, two key down-
stream effectors of TLR4. Similarly, in both PM patients and 
EAM mice, the expression of MyD88 and NF-κB was significantly 
increased as well (Figures 1 and 2).
FigUre 5 | The correlations of PM severity with toll-like receptor 4 (Tlr4)–MyD88 pathway, interferon-γ (iFn-γ), and interleukin-17a (il-17a). (a) HE 
stain showed the infiltrating cells in the muscle of experimental autoimmune myositis (EAM) mice at 1–4 weeks after the first immunization. Scale bar: 100 µm.  
(b) Muscle grading of inflammation at different time points (Ctrl). (c) Evaluation of muscular strength. **P < 0.001, vs. the controls. (D) The expression of TLR4, 
MyD88, NF-κB, IFN-γ, or IL-17A had a positive correlation with muscle grading of inflammation in EAM mice, respectively.
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FigUre 6 | Toll-like receptor 4 (Tlr4)–MyD88 pathway was required in polymyositis (PM). (a–D) HE stain showed the infiltrating cells in the muscle of 
normal mice and experimental autoimmune myositis (EAM) mice treated with normal saline only, lipopolysaccharide (LPS) or TAK-242, respectively. Scale bar: 
100 µm. The grading evaluation of inflammation was decreased and the muscular strength was stronger in EAM mice treated with TAK-242 (e,F). The mRNA 
expression of MyD88, NF-κB, IFN-γ, and IL-17A in muscle tissues of mice were upregulated after treatment with LPS and downregulated after treatment with 
TAK-242 [(g–J), respectively]. IFN-γ and IL-17A in the serum of mice increased or decreased after treatment with LPS or TAK-242, respectively (K,l).  
**P < 0.001, versus the EAM mice treated with normal saline only.
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It is known that the TLR4–MyD88 pathway involves the 
production of various inflammatory cytokines. Therefore, we 
also investigated the changes of cytokine expression in the 
serum of EAM mice. As expected, our results showed that the 
levels of IFN-γ, IL-1β, IL-6, IL-10, IL-12, IL-17A, TNF-α, and 
TGF-β were markedly elevated (Figure 3). However, a previous 
study showed the reduced Th1 and Th17 cells in PMBCs from 
PM patients (32). We proposed that this discrepancy might 
attribute to the differences between PM patients and PM mouse 
model. In animal models, increased IFN-γ-producing cells and 
IL-17A-producing cells were also observed in previous studies 
(33–37). Additionally, it was noted that IL-6 and IL-10 reached 
their maximal at 1  week after the first immunization whereas 
others reached their maximal level at 2 weeks. We proposed that 
IL-6 and IL-10 may play an important role in the early stages of 
PM progression (38).
Various cytokines can induce the differentiation of naïve T cells 
into different subpopulations (16, 39). It was reported that IL-6 
and TGF-β together may drive the differentiation of naïve T cells 
into Th17 cells (14, 40), and IL-6 and IFN-γ may be involved in 
Th1 differentiation (34, 41). In the present study, the expression 
of IFN-γ and IL-17A in muscle tissues of EAM mice was elevated 
(Figure 4) at a time that coincided with elevated expression of 
TLR4, MyD88, NF-κB as well as various cytokines (except IL-6 
and IL-10). Moreover, we found that the expression of TLR4, 
MyD88, NF-κB, IFN-γ, and IL-17A was positively correlated with 
the grading of muscle inflammation in EAM mice (Figure 5D). 
Therefore, our results suggested that the TLR4–MyD88 pathway 
and IFN-γ and IL-17Acells may play an important role in the 
development of PM.
Interestingly, our study showed that in the spleen of EAM 
mice, the expression of TLR4–MyD88 related molecules, IFN-γ, 
and IL-17A (Figure 2; Figure S1 in Supplementary Material) was 
decreased compared with the controls. Moreover, the expression 
was lowest at 2 weeks after immunization. These findings were 
converse to those in muscle tissue and have not been reported 
elsewhere. We presumed that these molecules are relocated from 
spleen to muscle by blood circulation or lymph recirculation, 
which could distribute lymphocytes between lymphoid tissue and 
other organs, arouse lymphocytes to remove invading pathogens, 
and promote antigen-activated lymphocytes to drain into local 
lymphoid tissue or organs. There, T cells, B cells, and APC may 
collaborate in the immune response for the production of effective 
lymphocytes (38, 42). The effective lymphocytes could migrate 
directly and intensively to the site of inflammation to induce an 
immune response (43, 44).
Geun-Tae Kim et al. (23) reported that the expression of TLR4 
was increased in few PM patients. In our research, muscle tissue 
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samples of 22 people with PM were studied. It was shown that 
the expression levels of TLR4 protein and TLR4 mRNA in muscle 
tissues of PM patients were significantly increased compared with 
the controls (Figures 1 and 2). Additionally, the relative expres-
sion levels of IFN-γ and IL-17A in muscle tissues of patients 
with PM were predominantly elevated compared with controls 
(Figure 4). This supported our conclusions from the EAM model.
These results were consistent with the inflammatory lesion 
grading trends of EAM mice. Moreover, we observed that muscle 
inflammation of EAM mice occurred at the same time point that 
EAM mouse strength was weakest (Figure 5) and the expression 
of TLR4 mRNA was highest (Figure  2). This trend suggested 
that TLR4 may trigger PM in the early immune responses 
(Figure 5). Based on above results, we used TLR4 agonist LPS 
and antagonist TAK-242 and found that TLR4 signaling was 
required in the development of PM. Furthermore, we revealed 
that TLR4-mediated IFN-γ and IL-17A played an important role 
in the inflammatory development of EAM, by using IFN-γ and 
IL-17A neutralization antibodies (Figures 6 and 7). Additionally, 
our results suggested that IFN-γ could alleviate but IL-17A could 
aggravate the inflammatory response (Figure 7).
Additionally, we still lacked the knowledge about how TLR4 
was activated in our EAM model. It is reported that exogenous 
sources (e.g., LPS) and endogenous TLR4 ligands have been 
identified from both the host tissues and cells. The endogenous 
intracellular triggers of TLR4 mainly include the DNA-binding 
protein high-mobility group box 1 (HMGB1) and cellular heat 
shock proteins (45). Previous studies have showed that HMGB1 
takes part in driving the inflammation of PM patients (46, 47). 
Therefore, we proposed that HMGB1 may be involved in our 
EAM model, and admittedly further studies should be done to 
address this question.
FigUre 7 | Different roles of toll-like receptor (Tlr4)-mediated interferon-γ (iFn-γ) and interleukin-17a (il-17a) in the course of development of 
experimental autoimmune myositis (eaM). (a–D) HE stain showed the infiltrating cells in the muscle of normal mice and EAM mice treated with normal saline 
only, anti-IFN-γ, or anti-IL-17 antibody, respectively. Scale bar: 100 µm. The grading evaluation of inflammation was increased or decreased but the muscular 
strength was weaker or stronger in EAM mice-treated anti-IFN-γ or anti-IL-17 antibody, respectively (e,F). The mRNA expression of IFN-γ was decreased but  
IL-17A increased in muscle tissues of EAM mice-treated anti-IL-17 or anti-IFN-γ antibody, respectively (g,h). IFN-γ or IL-17A was decreased or increased in the 
serum of mice-treated anti-IL-17 or anti-IFN-γ antibody, respectively (i,J). **P < 0.001, vs. the EAM mice treated with normal saline only.
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